Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update

被引：0

作者：

Basu, Supratik ^{[1
]}

Kumar, Shaji K. ^{[2
]}

Moreau, Philippe ^{[3
]}

Bahlis, Nizar ^{[4
]}

Facon, Thierry ^{[5
]}

Plesner, Torben ^{[6
,7
]}

Orlowski, Robert Z. ^{[8
]}

Nahi, Hareth ^{[9
]}

Hulin, Cyrille ^{[10
]}

Quach, Hang ^{[11
]}

Goldschmidt, Hartmut ^{[12
]}

O'Dwyer, Michael ^{[13
]}

Perrot, Aurore ^{[14
]}

Venner, Christopher P. ^{[15
]}

Weisel, Katja ^{[16
]}

Raje, Noopur ^{[17
]}

Tiab, Mourad ^{[18
]}

Macro, Margaret ^{[19
]}

Frenzel, Laurent ^{[20
]}

Leleu, Xavier ^{[21
]}

Pei, Huiling ^{[22
]}

Krevvata, Maria ^{[23
]}

Borgsten, Fredrik ^{[24
]}

Usmani, Saad Z. ^{[25
]}

机构：

[1] Royal Hosp Wolverhampton, Wolverhampton, England

[2] Mayo Clin Rochester, Dept Haematol, Rochester, MN USA

[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[4] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[5] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[6] Vejle Hosp, Vejle, Denmark

[7] Univ Southern Denmark, Vejle, Denmark

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[9] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Haematol, Dept Med, Stockholm, Sweden

[10] Univ Hosp Pessac, Dept Haematol, Hop Haut Leveque, Pessac, France

[11] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[12] Univ Heidelberg Hosp, GMMG Study Grp, Internal Med 5, Heidelberg, Germany

[13] NUI, Dept Med Haematol, Galway, Ireland

[14] UPS, Univ Toulouse, CHU Toulouse, IUCT O,Serv Hematol, Toulouse, France

[15] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[16] Univ Med Ctr Hamburg Eppendorf, Haematol & Bone Marrow Transplantat Sect Pneumol, Dept Oncol, Hamburg, Germany

[17] Massachusetts Gen Hosp, Ctr Multiple Myeloma, Canc Ctr, Boston, MA USA

[18] CHD Vendee, La Roche Sur Yon, France

[19] Ctr Hosp Univ CHU Caen, Caen, France

[20] Hop Necker Enfants Malad, Paris, France

[21] Hop Miletrie, CHU Poitiers, Poitiers, France

[22] Janssen Res & Dev LLC, Titusville, NJ USA

[23] Janssen Res & Dev LLC, Spring House, PA USA

[24] Janssen Res & Dev LLC, Raritan, NJ USA

[25] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-OR21

引用

页码：17 / 18

页数：2

共 50 条

[21] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Maclachlan, Kylee H.
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Shekarkhand, Tala
Rueda, Colin
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander
Usmani, Saad Z.
BLOOD, 2023, 142
[22] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
Horigome, Yuichi
Kamata, Hirotoshi
Michishita, Yusuke
Yokoyama, Maki
Tadera, Noriyuki
Hayama, Kei
Suzuki, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
[23] Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Moreau, Philippe
Facon, Thierry
Usmani, Saad Z.
Bahlis, Nizar
Raje, Noopur
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Wang, George
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
LEUKEMIA, 2025, 39 (03) : 710 - 719
[24] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Dingli, David
Go, Ronald S.
Warsame, Rahma
Kourelis, Taxiarchis
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Hwa, Yi
Fonder, Amie
Hobbs, Miriam
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
Wolfe, Eric
BLOOD, 2018, 132
[25] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
[26] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Moreau, Philippe
Facon, Thierry
Usmani, Saad
Bahlis, Nizar Jacques
Raje, Noopur
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
BLOOD, 2022, 140 : 7297 - 7300
[27] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Pei, H.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 317
[28] Speed and duration of response and patient reportsEndpoints (PROs) of daratumumab plus lenalidomide and dexamethasone therapy vs lenalidomide and dexamethasone in non-transplantable patients with newly diagnosed multiple myeloma: Phase 3 MAIA study
Goldschmidt, H.
Facon, T.
Kumar, S. K.
Plesner, T.
Moreau, P.
Bahlis, N.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Mace, J. R.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Pei, H.
Borgsten, F.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 90 - 91
[29] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
Usmani, Saad Z.
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Perrot, Aurore
Venner, Chris P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Van Rampelbergh, Rian
Tromp, Brenda
Delioukina, Maria
Facon, Thierry
BLOOD, 2021, 138
[30] Overall survival and progression-free survival by treatment duration with Daratumumab plus Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Moreau, Philippe
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Tromp, Brenda
Delioukina, Maria
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S1 - S1

← 1 2 3 4 5 →